Work

15300 Maintenance of response through up to 4-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial

Year: 2020

Type: article

Study design: Clinical Trial

Source: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2020.06.224

Authors: Kristian Reich, Michael Song, Megan Miller, Bruce Randazzo, Paraneedharan Ramachandran, Shu Li, Yin You, Chenglong Han, April W. Armstrong, Peter Foley, Kenneth B. Gordon

Institutions: University Medical Center Hamburg-Eppendorf, Janssen (Belgium), Janssen Research & Development (United States), Johnson & Johnson (United States), University of Southern California, The University of Melbourne, St Vincent's Hospital Melbourne, Skin and Cancer Foundation

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3028280065

FWCI:

Cites:

Cited by:

Related to: 10